1. Generics Bulletin
  2. >>Market Intelligence
  3. >>Company Rankings

The Generics Bulletin Top 50, Part Three: Newcomers Climb Into Bottom Table

As Some Firms Disappear From The Ranking This Year, Others Fill Their Places

 
• By Dave Wallace

In the third section of this year’s Generics Bulletin Top 50, a handful of new entrants make their way into the bottom of the rankings, while some volatility is seen among longstanding ranking companies.

Generics Bulletin Top 50 2022
Fresh firms are climbing into the Top 50 ranking • Source: Shutterstock

After the first part of this year’s Generics Bulletin Top 50 showed upheaval among the top 10 leading off-patent companies and the second part demonstrated movement among the mid-table players (see sidebar), this third and final section of the ranking sees a handful of new entrants making their way into the bottom of the chart, while others exit altogether.

Leading off the third table, we see India’s Biocon climbing from 35th to 31st position in our ranking, ahead of even greater growth for the company that is expected as...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Company Rankings

Generics Bulletin’s Top 50 Ranking For 2024

 
• By Dave Wallace

This article compiles all of the data from Generics Bulletin’s 2024 ranking of the Top 50 firms across the generics and biosimilars industry, including additional details of how the various financial figures stack up.

The Generics Bulletin Top 50, Part Three: Firms Fall Out Of Final Grouping

 
• By Dave Wallace

In the third instalment of this year’s Generics Bulletin Top 50, we look at some of the firms that have been eliminated from the bottom of our table as others have entered the picture.

The Generics Bulletin Top 50, Part Two: Major Shifts Bring Ups And Downs For Mid-Ranked Players

 
• By Dave Wallace

In the second part of Generics Bulletin’s Top 50, we see some companies rising up the rankings of generics and biosimilars players worldwide, passing others that are moving in the opposite direction.

The Generics Bulletin Top 50, Part One: Top Ten Ranking Conceals Changes For Industry Leaders

 
• By Dave Wallace

A deceptively familiar top 10 of generics and biosimilars industry leaders this year belies the significant evolutions seen for major off-patent players over the past 12 months. We reveal the changes under the surface in the first instalment of this year’s Generics Bulletin Top 50.

More from Market Intelligence

Formycon Faces Choppy Waters Amid US Biosimilar Pricing Storm

 
• By Dave Wallace

Unleashing a trio of major announcements, Formycon has indicated a gloomy outlook for US Stelara biosimilar pricing; revealed plans to pause commercialization of its Sandoz-partnered US Cimerli rival to Lucentis amid discounting from rivals; and set out ambitious plans to win FDA approval for its proposed Keytruda biosimilar without any Phase III data.

Vardenafil Leads UK Rises In January

 
• By Dave Wallace

Vardenafil led the steepest generic price rises in the UK in January, with the average cost of one presentation of the erectile dysfunction treatment more than trebling.

UK Gabapentin Prices Shoot Up In December

 
• By Dave Wallace

UK prices for gabapentin almost trebled in December, according to the latest figures from WaveData.